Dr. Gold was appointed President, Chief Executive Officer and a director in April 2010. He joined the Company with approximately 25 years of drug discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure at Prospect, Dr. Gold was founder and Chief Scientific Officer of Favrille, where he was an integral member of a team that raised more than $200 million to advance the company's lead oncology candidate through a pivotal Phase III clinical trial. He currently serves on the Board of Trustees of the Hope Funds for Cancer Research. Dr. Gold's academic qualifications include Postdoctoral Fellowships at the Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts University, Boston and a bachelor's degree in Biology from the University of California Los Angeles.
Dr. Mass has more than 20 years of experience as a medical oncologist in both clinical practice and clinical drug development. He held a number of leadership positions at Genentech from 1998 to 2009, most recently as Head of Medical Affairs, BioOncology, a position created to strategically integrate and optimize all of the non-sponsored clinical programs within the company’s oncology portfolio. He also served on the Executive Development Review Committee at Genentech, which was responsible for the review and approval of all sponsored clinical programs across the company’s therapeutic portfolio. Previously he served as clinical science leader for Herceptin ® from 1999 to 2002, Tarceva ® from 2002 to 2003, and Avastin ® , currently the leading oncology therapeutic worldwide, from 2003 to 2007. Prior to joining Genentech, he practiced Hematology and Medical Oncology from 1988 to 1998. Dr. Mass earned his bachelor’s degree in economics from Tufts University and his medical degree from Oregon Health & Science University. He is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology.
Mr. Zech joined as Chief Financial Officer in June 2010 with more than 35 years of experience in finance and accounting, including over 20 years in the life science industry. Previously, he served as Vice President, Finance and Chief Financial Officer at Pacira Pharmaceuticals, a specialty pharmaceutical company founded in 2007 through the acquisition of the former SkyePharma PLC (NASDAQ: SKYE; LSE:SKP) injectable business. He transitioned to Pacira Pharmaceuticals from SkyePharma Inc., where he joined in 1999 as Controller and Corporate Secretary. Prior to that, held senior finance positions at Stratagene, Advanced Tissue Sciences, Allied Holdings and Psicor. Mr. Zech earned his bachelor's degree in accounting from Lawrence Technological University and his MBA from the University of Detroit.
Mr. Urso joins MEI Pharma with more than two decades of experience in the life science industry, most recently as Chief Operating Officer and General Counsel at Tioga Pharmaceuticals, a privately held drug development company he co-founded in 2005. Previously, he was a Principal at Forward Ventures, where he was responsible for identifying and developing life science venture capital investments. Prior to joining Forward Ventures in 2002, Mr. Urso was Director of Corporate Development and Legal Affairs at DNA Sciences, Inc. Previously, he worked as an attorney in the corporate securities and licensing groups at Wilson Sonsini Goodrich & Rosati LLP and Cooley Godward LLP, after beginning his career as a bench scientist at SmithKline Beecham and the University of Pennsylvania Medical School. Mr. Urso received a J.D. from Harvard Law School and a B.A. in Molecular Biology and Philosophy from Reed College.
Dr. Levin was appointed as Vice President, Clinical Development and Medical Affairs in August 2013. Dr. Levin began her career as an undergraduate research scientist at the University of California, Los Angeles under the direction of Dr. Dennis Slamon, where, in collaboration with Genentech, she co-authored pivotal papers on Her-2/neu/Herceptin and its role in breast cancer. Most recently, Dr. Levin was with Pfizer Oncology, from 2007 to 2013, where she played an integral role in the clinical development of the Hedghog/cancer stem cell inhibitor PF-04449913, and led the biomarker plans for a variety of compounds, including immunotherapies, small molecule inhibitors and vaccines. She continues to see patients as a Volunteer Attending Physician at the University of California, San Diego. Dr. Levin earned her bachelor's degree in Biology and MS in Microbiology/Molecular Genetics at UCLA, her internal medicine training at the University of Southern California and her Hematology/Oncology Fellowship training at the University of Washington/Fred Hutchinson Cancer Research Center. Dr. Levin is Board certified/eligible in Internal Medicine, Medical Oncology and Hematology.
Dr. Moreno joined MEI Pharma as Vice President, Pre-Clinical Research in September 2010 and was appointed Vice President, Research and Development in July 2012. During the span, he was instrumental in advancing two of the Company's pre-clinical isoflavone-based drug candidates through investigational new drug-enabling studies and into clinical trials. Dr. Moreno has nearly 20 years of experience in the pharmaceutical industry, including positions of increasing responsibility at Merck, Amgen and Corvas International (acquired by Dendreon). From August 2003 to November 2007, he served as Senior Director of Chemistry at Dendreon, where he was responsible for designing and implementing the company's small-molecule research and development platform with a strategic emphasis on outsourcing. Dr. Moreno earned his bachelor's degree in Biology and Chemistry from Cornell University and his Ph.D. in Organic Chemistry from Harvard University.
Ms. Powell joined MEI Pharma in May 2013 as Vice President, Business Development, where she is responsible for licensing, valuation and opportunity assessment. From 2002 to 2012, Ms. Powell held a number of successive positions within Business Development at Amylin Pharmaceuticals, most recently serving as Sr. Director, Business Development. During her time with Amylin, she was responsible for numerous collaborative transactions and was involved in the sale of the company to Bristol-Myers Squibb. Prior to Amylin, she held several financial roles at large pharmaceutical companies, including Aventis (acquired by Sanofi) and Bristol-Myers Squibb. Ms. Powell earned her bachelor's degree in finance as well as her MBA from the College of William and Mary in Willamsburg, Virgina.
Mr. De Spain joined the Company in July 2010 with more than 15 years of investor relations and corporate communications experience, primarily for publicly traded biotechnology companies. Most recently, he served as Sr. Director, Investor Relations & Corporate Communications at Prometheus Laboratories, a pharmaceutical and diagnostics company, before its acquisition by Nestlé Health Science. Prior to that, he was Director, Investor Relations & Corporate Communications at Favrille, a cancer immunotherapy company. Previously, he served in similar roles of increasing responsibility at Anadys Pharmaceuticals (acquired by Roche), Sequenom and Sunrise Medical. He currently serves on the board of the San Diego chapter of the National Investor Relations Institute (NIRI). Mr. De Spain received his bachelor's degree in communication with a public relations emphasis from San Diego State University.